



Research Article

DK-MGAR101, an extract of adventitious roots of mountain ginseng, improves blood circulation by inhibiting endothelial cell injury, platelet aggregation, and thrombus formation



Hye Rim Seong ^{a,1}, Cuicui Wang ^{a,1}, Muhammad Irfan ^b, Young Eun Kim ^c,
Gooyoung Jung ^c, Sung Kyeong Park ^d, Tae Myoung Kim ^a, Ehn-Kyoung Choi ^a,
Man Hee Rhee ^b, Yun-Bae Kim ^{a,*}

^a College of Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea

^b College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea

^c Pharmaceutical Technology Institute, Dongkook Pharmaceutical Co., Ltd., Jincheon, Republic of Korea

^d Department of Beauty Care, Daejeon Health Institute of Technology, Daejeon, Republic of Korea

ARTICLE INFO

Article history:

Received 7 September 2021

Received in revised form

2 November 2021

Accepted 3 January 2022

Available online 12 January 2022

Keywords:

Adventitious root

Blood circulation

Ginsenoside

Mountain ginseng

Platelet aggregation

ABSTRACT

Background: Since ginsenosides exert an anti-thrombotic activity, blood flow-improving effects of DK-MGAR101, an extract of mountain ginseng adventitious roots (MGAR) containing various ginsenosides, were investigated in comparison with an extract of Korean Red Ginseng (ERG).

Methods: In Sprague-Dawley rats orally administered with DK-MGAR101 or ERG, oxidative carotid arterial thrombosis was induced with FeCl₃ (35%), and their blood flow and occlusion time were measured. To elucidate underlying mechanisms, the cytoprotective activities on rat aortic endothelial cells (RAOECs) exposed to hydrogen peroxide (H₂O₂) were confirmed. In addition, the inhibitory activities of DK-MGAR101 and ERG on agonist-induced platelet aggregation, thromboxane B₂ production, and ATP granule release from stimulated platelets as well as blood coagulation were analyzed.

Results: DK-MGAR101 containing high concentrations of Rb1, Rg1, Rg3, Rg5, and Rk1 ginsenosides (55.07 mg/g) was more effective than ERG (ginsenosides 8.45 mg/g) in protecting RAOECs against H₂O₂ cytotoxicity. DK-MGAR101 was superior to ERG not only in suppressing platelet aggregation, thromboxane B₂ production, and granule release, but also in delaying blood coagulation, FeCl₃-induced arterial occlusion, and thrombus formation.

Conclusions: The results indicate that DK-MGAR101 prevents blood vessel occlusion by suppressing platelet aggregation, thrombosis, and blood coagulation, in addition to endothelial cell injury.

© 2022 The Korean Society of Ginseng. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

It is well known that vascular endothelial injury is one of the initial triggering factors of atherosclerosis and thrombosis, resulting in cardiovascular and cerebrovascular diseases (CVDs) [1]. Following arterial endothelial injury, blood-coagulating factors such as collagen, adenosine diphosphate (ADP), thrombin, and von Willebrand Factors are generated. These factors induce adhesion to

the damaged intima, activation, and aggregation of platelets [2]. Eventually, aggregation of the stimulated platelets plays a central role for the thrombosis, blocking blood flow [3].

Activated platelets release ADP, thromboxane A₂ (TXA₂), and ATP from their alpha and dense granules for adherence to the injured arterial intima and for further autocrine activation [4]. As a strong inducer of platelet aggregation and vasoconstriction, TXA₂ is produced during vascular oxidative stress process, but rapidly converted to thromboxane B₂ (TXB₂) [5–7].

Aspirin is widely prescribed for blood flow improvement to prevent CVDs, based on its anti-thrombotic activity [8]. However, aspirin can cause gastro-intestinal adverse effects, and exacerbate respiratory and cutaneous diseases such as asthma and urticarial [9,10]. Thrombolytic tissue-type plasminogen activator, prescribed

* Corresponding author. College of Veterinary Medicine, Chungbuk National University, 1 Chungdaero Gaesin-dong, Cheongju, Chungbuk, 28644, Republic of Korea.

E-mail address: solar93@cbu.ac.kr (Y.-B. Kim).

¹ These authors contributed equally to this work.

for the emergency treatment of acute stroke, has a potential haemorrhagic adverse effect, too [11].

Panax ginseng Meyer may be the most-widely used herbal products for the improvement of immune function, cognitive function, blood flow, tumour prevention, and stamina in the world [12–14]. The effectiveness of ginsenosides covers improvement of circulatory problems such as ischemia [15], hypertension [16], and metabolic syndrome [17], based on their anti-oxidant and anti-fibrotic activities [18].

Wild mountain ginseng, naturally growing in shady forests in Asia continent, has been believed to be superior to cultivated ginseng in the active ingredients and pharmacological activities [19,20]. Notably, investigators have established tissue culture techniques of mountain ginseng using bioreactors [21,22], obtaining massive MGAR. Furthermore, high amounts of ginsenosides can be obtained via such tissue culture process of mountain ginseng, especially treating with methyl jasmonate [21,23]. Indeed, MGAR extracts have been reported to be effective on hypertension, hyperlipidemia, hepatitis and fibrosis, diabetes, tumour growth, and sexual dysfunction [24].

In the super-aging society, functional foods are very desirable not only as nutraceuticals to prevent various diseases, but also as a supportive therapy to medication and surgery. In many advanced countries, especially in Korea, ginseng products are approved as functional foods. There have been constant efforts to obtain higher amounts of ginsenosides. Obtaining high amounts of ginsenosides and confirming their effectiveness are important for both sides of scientific and industrial ginseng researches.

According to the previous reports, we assumed that MGAR would display beneficial effects on the thrombotic processes. So, we investigated whether DK-MGAR101, an extract of MGAR containing high concentrations of diverse ginsenosides including Rb1, Rg1, Rg3, Rg5, and Rk1, exert a potential anti-thrombotic activity, and suggested underlying action mechanisms.

2. Materials and methods

2.1. Preparation of DK-MGAR101 and ERG

DK-MGAR101 and ERG were provided by Dongkook Pharm (Jincheon, Korea). Adventitious roots of wild mountain ginseng were cultivated at Central Research Institute of Dongkook Pharmaceutical Co. and fresh roots of Panax ginseng were collected at Eumseong Ginseng Farm (Eumseong, Korea) in 2019. The raw ginsengs were authenticated by prof. K. Park (an expert in ginseng) at Chungbuk National University (CBNU), Korea. The ginseng roots were steamed for 1 h (121 °C, 1.2 bar), and treated with methyl jasmonate (100 µM) for 2 d [21–23]. The steamed ginseng roots were extracted with ethyl alcohol (70%, 60 °C, 8 h), and then freeze-concentrated to obtain DK-MGAR101 and ERG. In vivo studies, DK-MGAR101, ERG or aspirin (a reference material) was administered orally (5 mL/kg purified water).

2.2. Measurement of cytoprotective activity

RAOECs (R304-05 A; Sigma-Aldrich, St. Louis, USA) were cultivated referred to the manufacturer's instructions. The protective effects of DK-MGAR101 and ERG against the cytotoxicity of H₂O₂ were assessed from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. We adopted H₂O₂ as an oxidant for vascular endothelial injury to match the in vivo FeCl₃-induced thrombosis model, in which H₂O₂ is converted to highly toxic hydroxyl (OH) group according to the Fenton reaction.

For cytoprotective activity analysis, RAOECs (5 × 10⁴ cells/well) were seeded in a well plate, and 1 h later, incubated with DK-

MGAR101 or ERG (25–200 µg/mL) and H₂O₂ (60 µM) for 24 h. After washing twice and adding 50 mL MTT (stock solution 5 mg/mL, filtered), the cells were incubated for 4 h more [14]. The culture medium was removed, and formazan blue produced by surviving cells was extracted with 150 mL DMSO. The optical density of formazan was read at 570 nm using an ELISA reader.

2.3. Animals

Sprague-Dawley rats (male, 240–260 g) were purchased from Orient-Bio (Seongnam, Korea). The rats were housed in a specific pathogen-free room with controlled environment [temperature: 22 ± 2 °C, relative humidity: 40–70%, 12-h light-dark cycle (150–300 lux), ventilation: 12 times/h]. Filtered clean water and pellet chow were available ad libitum. The animal experiment protocols were approved by the CBNU Institutional Animal Care and Use Committee (Document No, CBNUA-1096-18-02).

2.4. Measurement of platelet aggregation

2.4.1. In vitro platelet aggregation assay

Blood sample was obtained from the rats into a syringe containing citrate coagulant. Platelet-rich plasma (PRP) was prepared through centrifugation-washing procedures, and washed platelets were adjusted to 3 × 10⁸ platelets/mL [25–27].

Aggregation of platelets was assessed with a turbidimetric method [28]. Platelet suspension with 1 mM CaCl₂ was pre-incubated with the test materials (DK-MGAR101, ERG or aspirin; 125–500 µg/mL) in an aggregometer (Chrono-Log, Harbertown, USA) under stirring at 37 °C. Following pre-incubation for 3 min, aggregation of the platelets was measured for 8 min after addition of collagen (0.625 µg/mL) or ADP (2.5 µM).

2.4.2. Ex vivo platelet aggregation assay

Rats (n = 6/group) were treated with DK-MGAR101, ERG (250 or 500 mg/kg) or aspirin (30 mg/kg) for 7 d. Forty min after the last day treatment, blood sample was collected. After preparation of PRP, aggregation of platelets was measured by inducing with collagen (0.625 µg/mL) or ADP (2.5 µM) as described above.

2.5. Measurement of TXB₂ and ATP release

2.5.1. In vitro TXB₂ release assay

TXB₂ released from stimulated platelets was measured using an ELISA kit (Dupont, Hayward, USA). Platelets suspension (4 × 10⁸ cells/mL) was pre-incubated with DK-MGAR101 or ERG (125–500 µg/mL) for 3 min, and aggregation was induced by collagen (0.625 µg/mL) or ADP (2.5 µM) described above. The reaction was stopped with ice-cold 2.5 mM EDTA and 2.5 mM indomethacin. After centrifugation at 1,200 rpm for 5 min, TXB₂ was analyzed [27–29].

2.5.2. Ex vivo TXB₂ and ATP release assays

Rats (n = 6/group) were administered DK-MGAR101, ERG (250 or 500 mg/kg) or aspirin (30 mg/kg) for 7 d. Forty min after the last administration, blood was withdrawn. After collection of PRP, TXB₂ was analyzed via ELISA after induction with collagen (0.625 µg/mL) or ADP (2.5 µM) as described above.

The supernatant after centrifugation of the platelets aggregated by collagen (0.625 µg/mL) or ADP (2.5 µM) was obtained. ATP in dense granules released from platelets was quantified with a commercial kit (Biomedical Research & Service Center, Redding, USA) using GloMax 20/20 luminometer (Promega, Madison, USA) [29].

2.6. Measurement of blood flow

Rats (n = 8/group) were orally given DK-MGAR101, ERG (125–500 mg/kg) or aspirin (30 mg/kg) for 3 wk. Forty min after the last administration, they were anaesthetized with urethane, and body temperature (36–37 °C) was maintained on a heating pad. After exposure of the right carotid artery, blood flow was recorded using a laser Doppler probe (AD Instruments, Colorado Springs, USA). One h after the last treatment, the artery was wrapped with a FeCl₃ (35%)-immersed filter paper (3 mm wide), near the laser probe, for 5 min to induce thrombosis [27–29]. During monitoring the blood stream for 40 min, the occlusion time was recorded. After sacrifice, and the arteries including FeCl₃-exposed area were cut for examination of thrombus in the artery.

2.7. Measurement of blood coagulation

After 40-min monitoring of blood flow, blood was collected into a tube containing citrate anti-coagulant. After centrifugation (2500 rpm, 15 min), the supernatant (platelet-poor plasma) was measured for coagulation times [prothrombin time (PT) and activated partial thromboplastin time (aPTT)] with Vetscan VSPRO (Abaxis Inc, Union City, USA) [30].

2.8. Thrombus weight and histopathology

After blood collection, thrombus regions of the arteries were cut at 1-mm intervals, and analyzed for entire length and weight of the thrombi.

For microscopic observation, the damaged arteries were fixed in a buffered-formalin. Paraffin-embedded slides were prepared, and stained with hematoxylin and eosin [27,28]. The proportions of platelet plug and blood clot in cross-sectioned vessels were analyzed using digital Image Inside analyzer (Focus, Seoul, Korea).

2.9. Statistical analysis

Data are presented as mean ± SE. Statistical analysis was performed with SPSS version 18.0 program (SPSS Inc, Chicago, USA). Differences among groups were analyzed with one-way ANOVA, followed by Dunnett's multiple-range test and Fisher's LSD test, at a level of P-value < 0.05.

3. Results

The total concentration of ginsenosides including Rb1, Rg1, Rg3, Rg5, and Rk1 was much higher in DK-MGAR101 (55.07 mg/g) than in ERG (8.45 mg/g) (Supplementary Fig. 1; Supplementary Table 1).

Exposure to H₂O₂ (60 μM) for 24 h decreased the survival rate of RAOECs to 43.2%. However, DK-MGAR101 protected against the H₂O₂ cytotoxicity: i.e., it significantly recovered the survival rate to 76.1–96.2% at 50–200 μg/mL (Fig. 1). By comparison, ERG exerted significant cytoprotective activity at only 100 and 200 μg/mL, increasing the survival rate to 70.2 and 74.8%, respectively.

DK-MGAR101 and ERG inhibited in vitro all the collagen (0.625 μg/mL)- and ADP (2.5 μM)-induced aggregation of platelets (Fig. 2A). Notably, DK-MGAR101 with higher concentration of ginsenosides was superior to ERG at all concentrations tested (125–500 μg/mL).

Such platelet aggregation-inhibitory effect was also achieved ex vivo: i.e., 7-d oral administration of DK-MGAR101 and ERG (250–500 mg/kg) strongly inhibited the platelet aggregation (Fig. 2B). DK-MGAR101 was more effective than ERG, showing a comparable activity at 500 mg/kg with aspirin (30 mg/kg).




Fig. 1. Effects of DK-MGAR101 and an extract of Korean Red Ginseng (ERG) on the hydrogen peroxide (H₂O₂)-induced cytotoxicity. Rat aortic endothelial cells were treated with DK-MGAR101 or ERG and H₂O₂ for 24 h *P < 0.05 from vehicle control.




Fig. 2. Effects of DK-MGAR101 and an extract of Korean Red Ginseng (ERG) on the agonist-stimulated platelet aggregation in vitro (A) and ex vivo (B). (A) Platelets were pre-incubated with DK-MGAR101 or ERG for 3 min at 37 °C, and stimulated with collagen (gray) or ADP (black) for 8 min. (B) Platelets obtained from DK-MGAR101-, ERG- or aspirin-treated rats were stimulated with collagen (gray) or ADP (black). *P < 0.05 from vehicle control.

DK-MGAR101 and ERG inhibited in vitro both the collagen- and ADP-induced thromboxane production, in which DK-MGAR101 was

superior to ERG (Fig. 3A). Also, DK-MGAR101, ERG, and aspirin decreased the thromboxane production ex vivo (n = 6/group) (Fig. 3B).

In addition, ATP release from the stimulated platelets was inhibited by the 3 compounds (DK-MGAR101, ERG, and aspirin),




Fig. 3. Effects of DK-MGAR101 and an extract of Korean Red Ginseng (ERG) on the thromboxane B₂ production (A: in vitro, B: ex vivo) and ATP release (C: ex vivo) from agonist-stimulated platelets. (A) Platelets were pre-incubated with DK-MGAR101 or ERG for 3 min at 37 °C, and stimulated with collagen (gray) or ADP (black) for 8 min. (B and C) Platelets obtained from DK-MGAR101-, ERG- or aspirin-treated rats were stimulated with collagen (gray) or ADP (black). *P < 0.05 from vehicle control.

indicative of the role of granular secretion for further activation and aggregation of platelets (Fig. 3C).

Following exposure to 35% FeCl₃ of the surface of arterial wall, the blood flow gradually decreased and near-fully ceased in 30 min (Fig. 4A). However, 3-wk oral treatment with DK-MGAR101 or ERG preserved the blood flow: i.e., the blood flow was preserved over 40 min in the animals given DK-MGAR101 or ERG (≥250 mg/kg), as observed in aspirin-treated rats (30 mg/kg). The arterial occlusion time in control animals was 26.0 min, calculated from the practical cessation time point when the blood steam velocity decreased to 10% of initial flow rate (Fig. 4B). DK-MGAR101 and ERG markedly delayed the occlusion time to 30.3–62.3 min and 29.6–49.4 min at 125–500 mg/kg, respectively. Expectedly, aspirin (30 mg/kg) also exhibited blood flow-improving activity, delaying mean occlusion time to 76.6 min.

Three-wk oral administration of DK-MGAR101 or ERG (125–500 mg/kg) did not remarkably delayed PT in the blood exposed to FeCl₃. However, both DK-MGAR101 (≥250 mg/kg) and ERG (375 mg/kg) significantly prolonged aPTT as shown in aspirin (30 mg/kg) (Supplementary Fig. 2).

Forty min after FeCl₃ application, the mean weight of thrombi produced was 0.99 ± 0.08 mg/mm in control group (Table 1). Treatment with DK-MGAR101 (375–500 mg/kg) significantly decreased the thrombus weight to 0.65–0.77 mg/mm. Such decreased thrombus formation was also observed in the rats treated with ERG (≥250 mg/kg) or aspirin (30 mg/kg).

As observed 40 min after application of FeCl₃, the arteries were near-fully plugged with thrombi in control animals (Fig. 5A),




Fig. 4. Change in arterial blood flow (A) and time to occlusion (B) after FeCl₃ application outside the carotid arterial wall of rats. DK-MGAR101, an extract of Korean Red Ginseng (ERG) or aspirin was orally treated for 3 wk prior to FeCl₃ challenge. •: vehicle (FeCl₃-induced) control, ▲: 125 mg/kg DK-MGAR101, ■: 250 mg/kg DK-MGAR101, ▼: 375 mg/kg DK-MGAR101, ◆: 500 mg/kg DK-MGAR101, △: 125 mg/kg ERG, □: 250 mg/kg ERG, ▽: 375 mg/kg ERG, ◇: 500 mg/kg ERG, ○: 30 mg/kg aspirin. *P < 0.05 from vehicle (FeCl₃ alone) control.

Table 1
Thrombus weight in the carotid arteries after application of FeCl₃ outside the arterial wall.

Treatment	Dose (mg/kg)	Thrombus (mg/mm)
FeCl ₃ alone	0	0.99 ± 0.08
DK-MGAR101	125	0.87 ± 0.06
	250	0.94 ± 0.04
	375	0.65 ± 0.10*
	500	0.77 ± 0.05*
ERG	125	0.83 ± 0.08
	250	0.78 ± 0.05*
	375	0.67 ± 0.04*
	500	0.73 ± 0.11*
Aspirin	30	0.78 ± 0.06*

DK-MGAR101, an extract of Korean Red Ginseng (ERG) or aspirin (30 mg/kg) were orally administered for 3 weeks prior to FeCl₃ exposure. *P < 0.05 from vehicle (FeCl₃ alone) control.

consisting of 79.1% blood clot and 20.9% platelet plug (Fig. 5B). However, following administration of DK-MGAR101, ERG or aspirin, the thrombi were relatively loose and showed larger portions of

permeable platelet plugs compared to the flow-blocking blood clots. Aspirin (30 mg/kg) enhanced the portion of platelet plugs to 48.5%. In comparison, DK-MGAR101 (125–500 mg/kg) increased the platelet plug ratio to 29.6–48.2%, and ERG (125–500 mg/kg) expanded to 22.3–41.0%, too. Notably, DK-MGAR101 was superior to ERG at all dose ranges.

4. Discussion

We investigated whether DK-MGAR101 containing ginsenosides Rb1, Rg1, Rg3, Rg5, and Rk1 higher than ERG has per-oral anti-thrombotic activity, since ERG is well-known blood flow enhancer [30]. Indeed, it was demonstrated that ginsenosides Rg3 and Rk1 inhibited platelet aggregation by reducing ATP-containing granule release, thromboxane production, and integrin α_{IIb}β₃ activation [30,31]. In addition, geometric isomers Rk1/Rg5 were found to exert diverse inhibitory activities against platelet aggregation, oxidative response, and inflammation [32]. Especially, they increased the expression of vascular endothelial nitric oxide synthase (eNOS) related to vasodilatation [33]. Therefore, we




Fig. 5. Representative findings of arterial thrombi (A) and the ratios of platelet plug (gray) to blood clot (black) in the thrombi (B) produced by FeCl₃ application. DK-MGAR101, an extract of Korean Red Ginseng (ERG) or aspirin (30 mg/kg) was orally treated for 3 wk prior to FeCl₃ challenge. ★: blood clot (reddish), ☆: platelet plug (gray).

attempted to find out that DK-MGAR101 might be effective for improvement of blood circulation via *in vitro* and *in vivo* assays: i.e., oxidative endothelial cell injury, platelet aggregation, and FeCl₃-induced arterial thrombosis.

Vascular endothelial injury is one of the major triggering factors of atherosclerosis and CVDs [1]. In our study, DK-MGAR101 exerted a substantial protective activity against H₂O₂-induced oxidative cytotoxicity in RAOECs, in which DK-MGAR101 containing higher Rb1 (18.15 mg/g) was more effective than ERG (2.01 mg/g), as inferred from that ginsenoside Rb1 reduced H₂O₂-induced dysfunction and aging of human umbilical vein endothelial cells (HUVECs) [34].

In addition, DK-MGAR101 and ERG delayed both the collagen- and ADP-induced platelet activation and thromboxane production, wherein DK-MGAR101 was more potent than ERG. Interestingly, ADP-induced platelet aggregation and related TBX₂ production *in vitro* were more sensitive to DK-MGAR101 and ERG than collagen-triggered aggregation. However, DK-MGAR101, ERG as well as aspirin were more effective on platelet responses to collagen than ADP *ex vivo*. The *in vivo* platelet aggregation is a complex process taking place mainly through 3 steps [35]. Based on the complex cascades of platelet aggregation, it is believed that the higher sensitivity to ADP may be due to an inhibition by ginsenosides on the direct interaction of soluble factors with surface receptor *in vitro*. By comparison, the ginsenosides and aspirin may predominantly control the early stage of collagen binding to platelets, their activation, and ATP release *in vivo*, in addition to their anti-inflammatory and anti-oxidant activities on the damaged endothelial cells [32,34].

Following vascular wall injury, collagen fibers exposed to circulating platelets play a crucial role in hemostasis by producing a physical barrier for blocking blood loss [35–37]. Collagen also activates platelets, and recruits more platelets to the lesions, and consolidates the thrombus [36]. Activated platelets change their shape, secrete granules, and finally, aggregate, which are triggered by collagen-induced an increase in [Ca²⁺]_i [38]. As reported for ginsenosides [30,39], the inhibitory activity of DK-MGAR101 for the collagen-induced aggregation of platelets may be due to suppressing Ca²⁺ influx by decreasing thromboxane production. Actually, collagen-mediated increase in platelet [Ca²⁺]_i was blocked by controlling thromboxane formation with cyclooxygenase inhibitors including aspirin [40–42]. Similarly, it was confirmed that the anti-platelet aggregation effect of ginsenosides including Rk1 was in part due to the reduced release of thromboxane [30,31].

In a previous report, a ginseng extract did not affect blood coagulation times such as PT and aPTT [30]. However, DK-MGAR101 and ERG delayed the aPTT, but not PT. Interestingly, aspirin prolonged only the aPTT, too. Such a discrepancy may be due to the exposure of the blood to FeCl₃ in our study: i.e., after oxidative stress of blood cells, the aPTT might be changed and affected by anti-oxidant and anti-inflammatory ginsenosides and aspirin. It is believed that delayed blood coagulation should influence the blood (fibrin) clot formation, and eventually improvement of blood flow.

Here, we evaluated the anti-thrombotic potentials of DK-MGAR101 and ERG in a FeCl₃-triggered arterial occlusion model, leading to oxidative vascular injury and occlusive thrombosis [28]. As shown in Fig. 4, oral treatment of DK-MGAR101 and ERG markedly delayed the occlusion time. Notably, anti-inflammatory and anti-oxidant activities of DK-MGAR101 rich in Rg1, Rk1, and Rg5 as well as aspirin might additionally contributed to the higher effectiveness than ERG [32,34].

In the FeCl₃-mediated thrombus formation model, the thrombi composed of platelets, fibrin, and entrapped RBCs. In humans, such type of thrombus is observed in the coronary arteries after heart attack, leading to fatal myocardial infarction [43]. In our

observation, the thrombi were divided into loose (gray) platelet plugs and compact (reddish) blood (fibrin) clots. Interestingly, DK-MGAR101, ERG, and aspirin lowered the ratio of impermeable blood clots, increasing the permeable platelet plugs, as implied from the delayed aPTT. Since fibrin polymers and clots are produced from fibrinogen by an enzyme thrombin, such effects of blood flow-improving compounds on the ratio of platelet plug/fibrin clot suggests that they have a potential to alter the composition and structure of fibrin meshwork. As demonstrated *ex vivo* platelet aggregation assay and *in vivo* thrombus analysis, ginsenosides and aspirin may interfere with the early step of collagen-induced hemostasis. Therefore, it is believed that through interruption of initial hemostasis, relatively-loose platelet plugs remained, so decreasing compact blood clot generation, and thereby letting the blood vessels obstruct slowly.

During processing of ginseng products, drying, steaming, puffing, and extraction conditions result in different amounts of ginsenosides [44]. It is of interest to note that addition of methyl jasmonate to tissue medium facilitate the accumulation of original and newly-generated ginsenosides [21]. Methyl jasmonate stimulated the ginsenoside biosynthetic pathway, and thereby enhanced the ginsenoside contents in adventitious roots [45,46].

Among ginsenosides, Rg3 is the most potent in blocking aggregation of platelets by decreasing Ca²⁺-mediated thromboxane formation and granule secretion [29,47]. Actually, Rg3 was rich in DK-MGAR101 (4.46 mg/g), by comparison in ERG (1.07 mg/g). More importantly, the contents of novel Rk1/Rg5, possessing anti-platelet aggregation, vaso-dilatating, anti-oxidant, and anti-inflammatory activities [28–30], were much higher in DK-MGAR101 (31.24 mg/g) than in ERG (4.96 mg/g). It was expected that such high contents of Rg3, Rg5, and Rk1 in DK-MGAR101 would display a high blood flow-improving activity, although there is a limitation to explain exact action mechanisms of the extracts DK-MGAR101 and ERG containing additional functional and non-functional ingredients.

Here, we investigated whether an extract of MGAR improves blood flow, since an extract of Korean Red Ginseng was approved as a functional food for blood flow enhancer by the Ministry of Food and Drug Safety, Korea. DK-MGAR101 containing high concentrations of Rb1, Rg1, Rg3, Rg5, and Rk1 improved blood circulation through inhibition of platelet aggregation triggered by innate inducers as well as thrombosis induced by oxidative endothelial damage. Therefore, DK-MGAR101 could be a promising natural candidate for the prevention and improvement of vascular circulation and CVDs.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgments

This work was supported in part by Dongkook Pharmaceutical Co., Ltd.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jgr.2022.01.001>.

References

- [1] Ramos KS, Melchert RB, Chacon E, Acosta Jr D. Toxic responses of the heart and vascular systems. In: Klaassen CD, editor. Casarett & Doull's toxicology. The basic science of poisons. New York: McGraw-Hill; 2001. p. 597–651.

- [2] Jackson SP, Nesbitt WS, Kulkarni S. Signalling events underlying thrombus formation. *J Thromb Haemostasis* 2003;1:1602–12.
- [3] Majid A, Delanty N, Kantor J. Antiplatelet agents for secondary prevention of ischemic stroke. *Ann Pharmacother* 2001;35:1241–7.
- [4] Cowan DH. Platelet adherence to collagen: role of prostaglandin-thromboxane synthesis. *Br J Haematol* 1981;49:425–34.
- [5] Dogne JM, Hanson J, de Leval X, et al. From the design to the clinical application of thromboxane modulators. *Curr Pharmaceut Des* 2006;12:903–23.
- [6] Arita H, Nakano T, Hanasaki K. Thromboxane A₂: its generation and role in platelet activation. *Prog Lipid Res* 1989;28:273–301.
- [7] Gilmer JF, Murphy MA, Shannon JA, Breen CG, Ryder SA, Clancy JM. Single oral dose study of two isosorbide-based aspirin prodrugs in the dog. *J Pharm Pharmacol* 2003;55:1351–7.
- [8] Peter FW, Franken RJ, Wang WZ, et al. Effect of low dose aspirin on thrombus formation at arterial and venous microanastomoses and on the tissue microcirculation. *Plast Reconstr Surg* 1997;99:1112–21.
- [9] Pavlidis P, Bjarnason I. Aspirin induced adverse effects on the small and large intestine. *Curr Pharmaceut Des* 2015;21:5089–93.
- [10] Cortellini G, Carusob C, Romano A. Aspirin challenge and desensitization: how, when and why. *Curr Opin Allergy Clin Immunol* 2017;17:247–54.
- [11] Mackman N. Triggers, targets and treatments for thrombosis. *Nature* 2008;451:914–8.
- [12] Ernst E. Panax ginseng: an overview of the clinical evidence. *J Ginseng Res* 2010;34:259–63.
- [13] Nam KY. The comparative understanding between red ginseng and white ginsengs, processed ginsengs (Panax ginseng Meyer). *J Ginseng Res* 2005;29:1–18.
- [14] Shin K, Guo H, Cha Y, Ban YH, Seo DW, Choi Y, et al. Cereboost™, an American ginseng extract, improves cognitive function via up-regulation of choline acetyltransferase expression and neuroprotection. *Regul Toxicol Pharmacol* 2016;78:53–8.
- [15] Shah ZA, Gilani RA, Sharma P, Vohora SB. Cerebroprotective effect of Korean ginseng tea against global and focal models of ischemia in rats. *J Ethnopharmacol* 2005;101:299–307.
- [16] Han K, Shin IC, Choi KJ, Yun YP, Hong JT, Oh KW. Korea red ginseng water extract increases nitric oxide concentrations in exhaled breath. *Nitric Oxide* 2005;12:159–62.
- [17] Lee E, Zhao H, Li D, Jeong C, Kim J, Kim Y. Effect of the MeOH extract of adventitious root culture of Panax ginseng on hyperlipidemic rat induced by high fat-rich diet. *Korean J Pharmacogn* 2003;34:179–84.
- [18] Lim H, Kim Y, Lee D, Cho S, Cho M. The antifibrotic and antioxidant activities of hot water extract of adventitious root culture of Panax ginseng (ARCP). *J Appl Biol Chem* 2007;50:78–84.
- [19] Seog H, Jung C, Kim Y, Park H. Phenolic acids and antioxidant activities of wild ginseng (Panax ginseng C.A. Meyer) leaves. *Food Sci Biotechnol* 2005;14:371–4.
- [20] Yamaguchi H, Matsuura H, Kasai R, et al. Analysis of saponins of wild Panax ginseng. *Chem Pharm Bull (Tokyo)* 1988;36:4177–81.
- [21] Paek K, Murthy HN, Hahn EJ, Zhong JJ. Large scale culture of ginseng adventitious roots for production of ginsenosides. *Adv Biochem Eng Biotechnol* 2009;113:151–176.
- [22] Sivakumar G. Bioreactor technology: a novel industrial tool for high-tech production of bioactive molecules and biopharmaceuticals from plant roots. *Biotechnol J* 2006;1:19–1427.
- [23] Sivakumar G, Yu K, Paek K. Production of biomass and ginsenosides from adventitious roots of Panax ginseng in bioreactor cultures. *Eng Life Sci* 2005;5:33–342.
- [24] Murthy HN, Dandin VS, Park SY, Paek KY. Quality, safety and efficacy profiling of ginseng adventitious roots produced in vitro. *Appl Microbiol Biotechnol* 2018;102:7309–17.
- [25] Jin YR, Cho MR, Ryu CK, et al. Antiplatelet activity of J78 (2-chloro-3-[2'-bromo, 4'-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A₂ receptor blockade with TXA₂ synthase inhibition and suppression of cytosolic Ca²⁺ mobilization. *J Pharmacol Exp Ther* 2005;312:214–9.
- [26] Lee JJ, Yang H, Yoo YM, et al. Morusinol extracted from *Morus alba* inhibits arterial thrombosis and modulates platelet activation for the treatment of cardiovascular disease. *J Atherosclerosis Thromb* 2012;19:516–22.
- [27] Jang JY, Kim TS, Cai J, et al. Nattokinase improves blood flow by inhibiting platelet aggregation and thrombus formation. *Lab Anim Res* 2013;29:221–5.
- [28] Jang JY, Kim TS, Cai J, et al. Perilla oil improves blood flow through inhibition of platelet aggregation and thrombus formation. *Lab Anim Res* 2014;30:21–7.
- [29] Lee SR, Park JH, Kim ND, Choi KJ. Inhibitory effects of ginsenoside Rg3 on platelet aggregation and its mechanism of action. *Korean J Ginseng Sci* 1997;21:132–40.
- [30] Jin YR, Yu JY, Lee JJ, et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. *Basic Clin Pharmacol Toxicol* 2007;100:170–5.
- [31] Shin JH, Kwon HW, Irfan M, Rhee MH, Lee DH. Ginsenoside Rk1 suppresses platelet mediated thrombus formation by downregulation of granule release and α_{IIb}β₃ activation. *J Ginseng Res* 2021;45:490–7.
- [32] Elshafay A, Tinh NX, Salman S, et al. Ginsenoside Rk1 bioactivity: a systematic review. *PeerJ* 2017;5:e3993.
- [33] Ying A, Yu QT, Guo L, et al. Structural-activity relationship of ginsenosides from steamed ginseng in the treatment of erectile dysfunction. *Am J Chin Med* 2018;46:137–55.
- [34] Zheng Z, Wang M, Cheng C, et al. Ginsenoside Rb1 reduces H₂O₂-induced HUVEC dysfunction by stimulating the sirtuin-1/AMP-activated protein kinase pathway. *Mol Med Rep* 2020;22:247–56.
- [35] Morton LF, Peachey AR, Barnes MJ. Platelet-reactive sites in collagens type I and type III. Evidence for separate adhesion and aggregatory sites. *Biochem J* 1989;258:157–63.
- [36] Poole AW, Watson SP. Regulation of cytosolic calcium by collagen in single human platelets. *Br J Pharmacol* 1995;115:101–6.
- [37] Cowan DH, Robertson AL, Shook P, Giroski P. Platelet adherence to collagen: role of plasma, ADP, and divalent cations. *Br J Haematol* 1981;47:257–67.
- [38] Roberts DE, McNicol A, Bose R. Mechanism of collagen activation in human platelets. *J Biol Chem* 2004;279:19421–30.
- [39] Jeon WK, Yoo BK, Kim YE, et al. Anti-platelet activity of tissue-cultured mountain ginseng adventitious roots in human whole blood. *Food Sci Biotechnol* 2008;17:1197–202.
- [40] Rittenhouse SE, Allen CL. Synergistic activation by collagen and 15-hydroxy-9 α,11 α-peroxidoprostanoic acid (PGH₂) of phosphatidylinositol metabolism and arachidonic acid release in human platelets. *J Clin Invest* 1982;70:1216–24.
- [41] McNicol A, Nickolaychuk BR. Inhibition of collagen-induced platelet activation by arachidonyl trifluoromethyl ketone. *Biochem Pharmacol* 1995;50:1795–802.
- [42] Feijge MA, Van Pampus EC, Lacabartaz-Porret C, et al. Inter-individual variability in Ca²⁺ signalling in platelets from healthy volunteers: effects of aspirin and relationship with expression of endomembrane Ca²⁺-ATPases. *Br J Haematol* 1988;102:850–9.
- [43] Lockyer S, Kambayashi J. Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. *J Cardiovasc Pharmacol* 1999;33:718–25.
- [44] Shin JH, Park YJ, Kim W, et al. Change of ginsenoside profiles in processed ginseng by drying, steaming, and puffing. *J Microbiol Biotechnol* 2019;29:222–9.
- [45] Yu KW, Gao W, Hahn EJ, Paek KY. Jasmonic acid improves ginsenoside accumulation in adventitious root culture of Panax ginseng C.A. Meyer. *Biochem Eng J* 2002;11:211–5.
- [46] Kim YS, Hahn EJ, Murthy HN, Paek KY. Adventitious root growth and ginsenoside accumulation in Panax ginseng cultures as affected by methyl jasmonate. *Biotechnol Lett* 2004;26:1619–22.
- [47] Ban YH, Cha Y, Choi J, et al. Blood flow-improving activity of methyl jasmonate-treated adventitious roots of mountain ginseng. *Lab Anim Res* 2017;33:105–13.